Thromb Haemost 1968; 20(01/02): 234-246
DOI: 10.1055/s-0038-1651263
Originalarbeiten – Original Articles – Travaux Originaux
Schattauer GmbH

On the Nature of Antithrombin V

H Vinazzer
1   Blood Coagulation Laboratory Dr. Vinazzer (Head: Dr. H. Vinazzer), Linz (Austria)
,
F Reinhardt
2   Medical Department, Hospital of the Barmherzigen Brüder (Head: Doz. Dr. F. Reinhardt), Linz (Austria)
› Author Affiliations
Further Information

Publication History

Publication Date:
27 June 2018 (online)

Preview

Summary

Two cases of myeloma with a severe bleeding tendency due to the occurrence of antithrombin V could be observed. The following data on this inhibitor were collected:

1. The inhibitor activity could be temporarily suppressed by long term treatment with cortisone. The long lag period indicates that a cellular function must be responsible for the production of antithrombin V.

2. Various tests confirmed that antithrombin V is a true inhibitor of thrombin and not a polymerization inhibitor.

3. The esterase activity of thrombin is not inhibited by antithrombin V.

4. The reptilase activity is reduced by antithrombin V.

5. Highly concentrated antithrombin V could be extracted from a patient’s bone marrow. This led to the assumption that the bone marrow participates in the production of antithrombin V.

6. Sephadex fractionation of the serum revealed that the entire antithrombin V activity moves with the A-fraction.

7. On ultrafiltration, the antithrombin activity remained on the diaphragm, indicating that antithrombin V is a true protein and not a split product.